Pacira Q2 revenue slightly beats estimates; cuts FY outlook
PCRX•Outlook
- Pacira sees 2026 total revenue of $735 mln to $760 mln, down from prior $745 mln to $770 mln
- Company expects 2026 EXPAREL net product sales of $600 mln to $620 mln
- Pacira forecasts 2026 non-GAAP gross margin of 77% to 79%
Overview
- US non-opioid pain therapies maker's Q2 revenue rose 6%, slightly beating analyst expectations
- Adjusted net income and adjusted EBITDA for Q2 both beat analyst estimates
- Company completed divestiture of iovera° business to Zimmer Biomet in July
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Slight Beat* | $192.40 mln | $190.82 mln (5 Analysts) |
| Q2 Adjusted Net Income | Beat | $29.50 mln | $27.32 mln (4 Analysts) |
| Q2 Net Income | $4.70 mln | ||
| Q2 Adjusted EBITDA | Beat | $48.70 mln | $40.73 mln (3 Analysts) |
| Q2 Cash & Investments | $251 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
